PeptideDB

Chlorpyrifos-oxon 5598-15-2

Chlorpyrifos-oxon 5598-15-2

CAS No.: 5598-15-2

Chlorpyrifos-oxo, an bioactive metabolite of Chlorpyrifos, is a potent phosphorylating agent that effectively inhibits A
Data collection:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Chlorpyrifos-oxo, an bioactive metabolite of Chlorpyrifos, is a potent phosphorylating agent that effectively inhibits AChE. Chlorpyrifos-oxo induces cross-links between tubulin subunits and disrupts microtubule function.

Physicochemical Properties


Molecular Formula C9H11CL3NO4P
Molecular Weight 334.52
Exact Mass 332.949
CAS # 5598-15-2
Related CAS # Chlorpyrifos-oxon-d10;1794779-85-3
PubChem CID 21804
Appearance White to off-white <43°C powder,>53°C liquid
Density 1.461g/cm3
Boiling Point 357.8ºC at 760mmHg
Flash Point 170.2ºC
Index of Refraction 1.523
LogP 4.601
Hydrogen Bond Donor Count 0
Hydrogen Bond Acceptor Count 5
Rotatable Bond Count 6
Heavy Atom Count 18
Complexity 300
Defined Atom Stereocenter Count 0
SMILES

CCOP(OC1=NC(Cl)=C(Cl)C=C1Cl)(=O)OCC

InChi Key OTMOUPHCTWPNSL-UHFFFAOYSA-N
InChi Code

InChI=1S/C9H11Cl3NO4P/c1-3-15-18(14,16-4-2)17-9-7(11)5-6(10)8(12)13-9/h5H,3-4H2,1-2H3
Chemical Name

diethyl (3,5,6-trichloropyridin-2-yl) phosphate
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture.
Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


ln Vitro Protein aggregation occurs when 1.5 mM chlorpyrifos-oxon (CPO) is applied to tubulin. Nonetheless, cross-linked trimers between chlorpyrifos and oxon are visible even at 1.5 μM. Chlorpyrifos-oxon facilitates tubulin monomers' isopeptide bond cross-linking to form multimers[2]. Neurite outgrowth was hindered in PC12 cells cultured for 24 hours when exposed to chlorpyrifos at a dosage 10-fold lower than that which inhibits AChE activity (3.0 μM), but neurite outgrowth is inhibited at 1.0 nM by chlorpyrifos-oxon[3].
ln Vivo Human liver microsomes quickly detoxify chlorpyrifos-oxon (CPO) by glutathione-S-transferase and CYP-dependent deethylation and dearylation. Furthermore, Chlorpyrifos-oxon may be quickly degraded or scavenged in the liver by interactions with A-esterases like paraoxonase 1 (PON 1) or B-esterases such carboxylesterase and butyrylcholinesterase (BChE)[1]. Following treatment with Chlorpyrifos-oxon (3 mg/kg, ip; once); wild-type mice, the microtubule dimensions of the treated mice resemble those of the control mice by almost 60%. Mice exposed to chlorpyrifos-oxon had microtubules with aberrant structures and covalently changed amino acids, which may indicate a disruption in microtubule function[4].
ADME/Pharmacokinetics Metabolism / Metabolites
Chlorpyrifos-oxon has known human metabolites that include Diethyl phosphorothioate and 3,5,6-Trichloro-2-pyridinol.
Chlorpyrifos-oxon is a known human metabolite of Chlorpyrifos.
Metabolism of organophosphates occurs principally by oxidation, by hydrolysis via esterases and by reaction with glutathione. Demethylation and glucuronidation may also occur. Oxidation of organophosphorus pesticides may result in moderately toxic products. In general, phosphorothioates are not directly toxic but require oxidative metabolism to the proximal toxin. The glutathione transferase reactions produce products that are, in most cases, of low toxicity. Paraoxonase (PON1) is a key enzyme in the metabolism of organophosphates. PON1 can inactivate some organophosphates through hydrolysis. PON1 hydrolyzes the active metabolites in several organophosphates insecticides as well as, nerve agents such as soman, sarin, and VX. The presence of PON1 polymorphisms causes there to be different enzyme levels and catalytic efficiency of this esterase, which in turn suggests that different individuals may be more susceptible to the toxic effect of organophosphate exposure.
References

[1]. Extreme variability in the formation of chlorpyrifos oxon (CPO) in patients poisoned by chlorpyrifos (CPF). Biochem Pharmacol. 2009 Sep 1;78(5):531-7.

[2]. Chlorpyrifos oxon promotes tubulin aggregation via isopeptide cross-linking between diethoxyphospho-Lys and Glu or Asp: Implications for neurotoxicity. J Biol Chem. 2018 Aug 31;293(35):13566-13577.

[3]. Chlorpyrifos and chlorpyrifos oxon impair the transport of membrane bound organelles in rat cortical axons. Neurotoxicology. 2017 Sep;62:111-123.

[4]. Mice treated with chlorpyrifos or chlorpyrifos oxon have organophosphorylated tubulin in the brain and disrupted microtubule structures, suggesting a role for tubulin in neurotoxicity associated with exposure to organophosphorus agents.

Additional Infomation Chlorpyrifos oxon examines the risk of acute toxicity in soil microbes by comparing data on environmental concentrations of these pesticides to toxic concentrations. In animals, chlorpyrifos transforms to chlorpyrifos-oxon, which is about 3000 times as potent against the nervous system as chlorpyrifos itself.

Solubility Data


Solubility (In Vitro) DMSO: 100 mg/mL (298.94 mM)
Solubility (In Vivo) Solubility in Formulation 1: ≥ 2.5 mg/mL (7.47 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 2.5 mg/mL (7.47 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

Solubility in Formulation 3: ≥ 2.5 mg/mL (7.47 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.9894 mL 14.9468 mL 29.8936 mL
5 mM 0.5979 mL 2.9894 mL 5.9787 mL
10 mM 0.2989 mL 1.4947 mL 2.9894 mL
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.